



Association of *FTO* and *PPARG* polymorphisms with obesity in Portuguese women

Fábio Ferreira Carlos^{1,2}

José Silva-Nunes^{3,4}

Orfeu Flores¹

Miguel Brito³

Gonçalo Doria¹

Luísa Veiga³

Pedro Viana Baptista¹

¹Centro de Investigação em Genética Molecular Humana, Universidade Nova de Lisboa, Caparica, Portugal;

²Investigação e Serviços em Ciências Biológicas, Stab Vida, Caparica, Portugal; ³Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, Portugal; ⁴Endocrinology Department, Curry Cabral Hospital, Lisbon, Portugal

Purpose: We evaluated the association between risk of obesity in the Portuguese population and two obesity-related single-nucleotide gene polymorphisms: *fat-mass and obesity-associated (FTO)* rs9939609 and *peroxisome proliferator-activated receptor gamma (PPARG)* rs1801282.

Patients and methods: A total of 194 Portuguese premenopausal female Caucasians aged between 18 and 50 years (95 with body mass index [BMI] ≥ 30 g/m², 99 controls with BMI 18.5–24.9 kg/m²) participated in this study. The association of the single-nucleotide polymorphisms with obesity was determined by odds ratio calculation with 95% confidence intervals.

Results: Significant differences in allelic expression of *FTO* rs9939609 ($P < 0.05$) were found between control and case groups, indicating a 2.5-higher risk for obesity in the presence of both risk alleles when comparing the control group with the entire obese group. A fourfold-higher risk was found for subjects with class III obesity compared to those with classes I and II. No significant differences in BMI were found between the control and case groups for *PPARG* rs1801282 ($P > 0.05$).

Conclusion: For the first time, a study involving an adult Portuguese population shows that individuals harboring both risk alleles in the *FTO* gene locus are at higher risk for obesity, which is in agreement to what has been reported for other European populations.

Keywords: rs9939609, rs1801282, BMI, SNP, odds ratio

Introduction

Obesity prevalence has grown dramatically in recent decades and shows no signs of decline. According to the World Health Organization (WHO), it is estimated that 1.5 billion people are overweight, of which 500 million are obese.¹ Obesity and overweight result from a combination of genetic background, environmental, and lifestyle factors, and are intrinsically associated with increased risk of associated disease, such as hypertension, dyslipidemia, and type 2 diabetes.² Several gene-association studies have led to the identification of different loci (single nucleotide polymorphisms [SNPs]) that contribute to obesity and overweight.³ One of these SNPs, rs9939609, in the *fat-mass and obesity-associated (FTO)* gene, has been described as a risk factor to obesity, and strongly associated with body mass index (BMI) increments in European adults.⁴ Frayling and colleagues⁴ demonstrated that the presence of the risk allele A is cumulative and represent a 20% higher risk for the development of obesity and 13% for the development of overweight. This association was later confirmed by several other studies in different populations.^{5–7} Another gene playing an important role in

Correspondence: Pedro Viana Baptista
Centro de Investigação em Genética Molecular Humana, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Campus de Caparica, Caparica 2829-516, Portugal
Tel/Fax +351 21 294 8530
Email pmvb@fct.unl.pt

obesity is *peroxisome proliferator-activated receptor gamma* (*PPARG*), which regulates the adipocyte differentiation, thus influencing BMI, as well as glucose metabolism.⁸ In particular, SNP rs1801282 has been associated with obesity in different populations, with a clear identification of the risk allele G.^{9–11}

To date, there are no data on the involvement of either of these SNPs in obesity in the adult Portuguese population, and whether the same pattern of risk alleles is present. Here, we report on the first association study between these SNPs and obesity for the adult Portuguese population, which can provide useful data for the clinical management and risk assessment of obesity.

Materials and methods

Subjects

All 194 subjects participating in the study were premenopausal Caucasian Portuguese females between 18 and 50 years old, duly informed about the study and having signed an informed consent.

As a control group were 99 healthy subjects showing a BMI ranging between 18.5 and 24.9 kg/m² with body-weight variation inferior to 10% in the last year. These subjects were either selected during a routine health check or belonged to the staff of Curry Cabral Hospital (Lisbon, Portugal).

The case group was composed of 95 subjects showing a BMI ≥ 30 kg/m² with body-weight variation inferior to 10% in the last year. These subjects were all attending the Endocrinology Department of Curry Cabral Hospital.

Sample collection

Samples were collected from peripheral total blood and preserved at -80°C . For analysis, 2 mL of blood was transferred to individual FTA (Whatman, Maidstone, UK) microcards, and DNA was purified according to the manufacturer's protocol.

Polymorphism analysis

Polymerase chain reaction (PCR) amplifications were performed on a Biometra TGradient Thermocycler (Göttingen, Germany) in 25 μL final volume with Master Mix and DNA Surf Hot Taq Polymerase (10 U/ μL) (Stab Vida, Lisbon, Portugal) with the following thermal cycling conditions: initial 15-minute denaturation at 96°C , followed by 30 amplification cycles of denaturation at 94°C for 1 minute, annealing at 59°C for 1 minute, elongation at 70°C for 1 minute, and a final elongation at 70°C for 5 minutes. Primers for *PPARG* locus (GenBank accession no NC_000003.11):

PPARG-F 5'-CAATTCAAGCCCAGTCCTTT-3' and *PPARG*-R 5'-TTATCTCTGTGCATGGCTCC-3'. Primers for *FTO* locus (GenBank accession no NC_000016.9): *FTO*-F 5'-GCAAAATGGCAACACACACT-3' and *FTO*-R 5'-AACACCATCCTTGGGCTG-3'.

SNP identification was performed via direct sequencing. Sequencing reactions were carried out with 100 ng/100 bp of the previously PCR-amplified product using Big Dye version 3.1 technology (Life Technologies, Carlsbad, CA, USA) in an Applied Biosystems 3730XL DNA analyzer.

Statistical analysis

To determine the normality of the continuous variables (age), Student's *t*-test was used. To determine the differences between genotype groups of each SNP and anthropometric traits, one-way analyses of variance and a post hoc Bonferroni test were used. All odds ratio (OR) analysis was performed using binary logistic regression with 95% confidence interval (CI) to determine the risk of each loci to obesity and the respective *P*-value. All statistical analyses were carried out using SPSS software version 20 (IBM, Armonk, NY, USA).

Results

Table 1 presents the descriptive analyses of the subjects subdivided by their phenotype group. Figure 1 shows the population characterization by allele and genotype frequencies for *FTO* and *PPARG* SNPs. Significant differences ($P < 0.05$) were found only among the different genotypes of *FTO* rs9939609 for BMI, fat mass, and waist circumference. No other anthropometric traits were statistically different for *FTO* rs9939609 or *PPARG* rs1801282. Genotype frequencies for *FTO* rs9939609 were 24.74% T/T, 56.70% A/T, and 18.56% A/A. When comparing case and control groups, no significant deviation from the Hardy–Weinberg equilibrium of allele frequencies was observed for this locus ($P = 0.053$), with a majority of individuals being heterozygous (A/T). Data showed that the T allele is more frequent in subjects with BMI values between 18.5 and 24.9 kg/m², whereas the A allele is preminent in subjects with BMI ≥ 30 kg/m².

For *PPARG* rs1801282, the allele frequencies were 80.93% for homozygous C/C, 1.03% for homozygous G/G, and 18.04% for heterozygous C/G. Again, no significant deviation from the Hardy–Weinberg equilibrium of allele frequencies was observed for *PPARG* rs1801282 ($P = 0.97$).

The presence of the A allele in *FTO* rs9939609 does not per se confer risk for obesity in the studied population. However, significant differences in allele frequencies between

Table 1 Anthropometric data of all subjects subdivided by phenotype

Anthropometric measures	Total	Phenotype	
		Normal	Obese
n	194	99	95
Age (years)	34.19 (±8.22)	34.24 (±8.30)	34.12 (±8.14)
BMI (kg/m ²)	32.28 (±12.44)	21.42 (±1.69)	43.60 (±7.83)
Fat mass (kg)	33.59 (±22.43)	14.32 (±3.61)	54 (±14.88)
Fat mass (%)	36.22 (±12.25)	25.30 (±4.67)	47.61 (±5.30)
Waist (cm)	94.19 (±25.72)	71.75 (±5.85)	117.57 (±15.49)
Waist/hip ratio	0.80 (±0.09)	0.74 (±0.05)	0.87 (±0.08)

Notes: Obesity status: normal (BMI between 18.5 and 24.9 kg/m²), obese (BMI ≥ 30 kg/m²); all data presented as means ± standard deviation.

Abbreviation: BMI, body mass index.

the control and case groups were found for *FTO* rs9939609 ($P < 0.05$), indicating a 2.5-fold higher risk for obesity for homozygous A/A individuals (OR=2.571, CI 1.048–6.308; $P = 0.039$). Comparison of homozygous A/A individuals with T allele carriers (either homozygous T/T or heterozygous A/T) clearly shows a significant association of homozygous A/A with obesity (OR=2.451, CI 1.145–5.243; $P = 0.021$) (Table 2A).

What is more striking is the allelic expression of A/A homozygosity in subjects with a BMI ≥ 40 kg/m², ie, class III obesity. Considering this subgroup of obese women compared to those with class I and class II obesity, an OR=4.044 (CI 1.099–14.878; $P = 0.035$) was found (Table 2B).

Analysis of *PPARG* rs1801282 showed no association with obesity ($P > 0.05$) within the studied population.

Discussion

The worldwide prevalence of obesity has been increasing dramatically in the last few decades, and Portugal is no exception, where a 13.8% prevalence of obesity has been recorded.¹² Association studies have highlighted the influence of SNPs in obesity, with particular focus on *FTO* rs9939609.^{13,14} Thus far, no data on the possible association of this SNP to obesity in the adult Portuguese population has been reported. Here, for the first time, we demonstrate an association between the *FTO* rs9939609 homozygous AA genotype and increased BMI when compared to homozygous TT. Significant differences were found between control and case group confirming the increased risk for obesity of homozygous AA at this locus. Also, with the post hoc Bonferroni test, it was




Figure 1 Population characteristics, in function of the respective genotype (upper). Genotype and allele frequencies (bottom) obtained for each single-nucleotide polymorphism. White bars – all subjects, grey bars – controls and black bars – case. (A) Genotype frequencies for fat-mass and obesity-associated (*FTO*) rs9939609; (B) allele frequencies for *FTO* rs9939609; (C) genotype frequencies for peroxisome proliferator-activated receptor gamma (*PPARG*) rs1801282; (D) allele frequencies for *PPARG* rs1801282.

Note: *Significant differences between groups were found for these cases.

Table 2 Odds ratio (OR) values between case and control groups for risk to obesity for allele A in *fat-mass and obesity-associated (FTO)* rs9939609 and G in *peroxisome proliferator-activated receptor gamma (PPARG)* rs1801282, and between BMI ≥ 30 – < 40 kg/m² and BMI ≥ 40 kg/m² for risk for obesity for allele A in *FTO* rs9939609 and allele G in *PPARG* rs1801282 only in the case group

	<i>FTO</i> (rs9939609)			<i>PPARG</i> (rs1801282)		
		OR ^a (95% CI)	P-value		OR ^a (95% CI)	P-value
Case vs control	T/T	1 (reference)	–	C/C	1 (reference)	–
	A/T	1.071 (0.541–2.121)	0.843	C/G	0.658 (0.312–1.387)	0.271
	A/A	2.571* (1.048–6.308)	0.039	C/C + G/C ^b	1 (reference)	–
	T/T + A/T ^b	1 (reference)	–	G/G	0.752 (0.366–1.548)	0.439
	A/A	2.451* (1.145–5.243)	0.021			
Case vs case	T/T + A/T ^b	1 (reference)	–	C/C + G/C ^b	1 (reference)	–
	A/A	4.044* (1.099–14.878)	0.035	G/G	0.431 (0.026–7.134)	0.556

Notes: ^aAll ORs were calculated by logistic regression; ^bvalues were considered as reference; *significant difference found.

possible to determine that individuals with both A alleles in *FTO* rs9939609 show 6.37 ± 2.35 ($P=0.022$) higher BMI, 11.99 ± 4.86 kg ($P=0.043$) higher body-fat mass and 13.31 ± 4.87 cm ($P=0.020$) higher waist circumference compared to T-allele carriers. These data are in clear agreement with what has been reported for other populations of European origin.^{5–7,15,16} Our data show that in the adult Portuguese population, this polymorphism confers an even higher risk for class III obesity (BMI > 40 kg/m²). This may allow identification of those individuals at increased risk and target them for an earlier clinical and lifestyle intervention. This idea has been recently reinforced by the report of Albuquerque and colleagues showing a strong association of *FTO* rs9939609 with obesity in Portuguese children.¹⁷ Together, these data may prove useful for a structured public health strategy within the European Union.

Conversely, *PPARG* rs1801282 showed no association with obesity within the studied population, as no significant difference was found between control and case subjects ($P > 0.05$). In European populations, *PPARG* rs1801282 has shown association with obesity and higher BMI for homozygous carriers of the G allele ($P < 0.05$).¹⁰ Nevertheless, no association was found in other studies,^{18–20} indicating that this SNP may differ between populations and probably should not be considered as a strong genetic marker to evaluate risk for obesity as *FTO* rs9939609 is. Despite reports on a relation between *PPARG* rs1801282 and diabetes type 2,²¹ we observed no relation in our study ($P > 0.05$). The relevance of *PPARG* rs1801282 as a genetic marker to assess risk for obesity and high insulin levels in premenopausal Portuguese women is, therefore, negligible.

Conclusion

Thus far, this is the first association study involving obesity-related genetic polymorphisms in the adult Portuguese population. Data show that *FTO* rs9939609 could be useful for the clinical management of obese women. Nevertheless, additional data are

required, namely inclusion of males and youth subjects, to fully characterize the involvement of these loci in the development of obesity within the Portuguese population.

Acknowledgments

This work was supported by Stab Vida, Lda; FCT/MEC (PEst-OE/SAU/UI0009/2011 – CIGMH) and SFRH/BDE/51103/2010 for FFC.

Disclosure

The authors report no conflicts of interest in this work.

References

- [No authors listed]. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. *World Health Organ Tech Rep Ser.* 2000;894:i–xii, 1–253.
- Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. *JAMA.* 2003;289:76–79.
- Rankinen T, Zuberi A, Chagnon Y, et al. The human obesity gene map: the 2005 update. *Obesity.* 2006;14:529–644.
- Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the *FTO* gene is associated with body mass index and predisposes to childhood and adult obesity. *Science.* 2007;316:889–894.
- González-Sánchez JL, Zabena C, Martínez-Larrad MT, Martínez-Calatrava MJ, Pérez-Barba M, Serrano-Ríos M. Variant rs9939609 in the *FTO* gene is associated with obesity in an adult population from Spain. *Clin Endocrinol (Oxf).* 2009;70(3):390–393.
- Zimmermann E, Skogstrand K, Hougaard DM, et al. Influences of the common *FTO* rs9939609 variant on inflammatory markers throughout a broad range of body mass index. *PLoS One.* 2011;6:e15958.
- Sentinelli F, Incani M, Coccia F, et al. Association of *FTO* polymorphisms with early age of obesity in obese Italian subjects. *Exp Diabetes Res.* 2012;2012:872176.
- Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. *PPARG* gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. *Mol Cell Biol.* 1995;15:351–357.
- Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR-gamma) gene in diabetic Caucasians: identification of a pro12ala *PPAR-gamma-2* missense mutation. *Biochem Biophys Res Commun.* 1997;241:270–274.
- Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene pro12ala variant on body mass index: a meta-analysis. *J Med Genet.* 2003;40:773–780.

11. Dedoussis GV, Vidra N, Butler J, et al. Peroxisome proliferator-activated receptor-gamma (PPARgamma) Pro12 Ala polymorphism and risk for pediatric obesity. *Clin Chem Lab Med*. 2009;47:1047–1050.
12. do Carmo I, Dos Santos O, Camolas J, et al. Overweight and obesity in Portugal: national prevalence in 2003–2005. *Obes Rev*. 2008;9:11–19.
13. Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet*. 2007;3:1200–1210.
14. Li H, Kilpeläinen TO, Liu C, et al. Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. *Diabetologia*. 2012;4:981–995.
15. Zavattari P, Loche A, Pilia S, et al. rs9939609 in the FTO gene is associated with obesity but not with several biochemical parameters in Sardinian obese children. *Ann Hum Genet*. 2011;75:648–654.
16. Liu G, Zhu H, Lagou V, et al. FTO variant rs9939609 is associated with body mass index and waist circumference, but not with energy intake or physical activity in European- and African-American youth. *BMC Med Genet*. 2010;11:57.
17. Albuquerque D, Nóbrega C, Manco L. Association of FTO polymorphisms with obesity and obesity-related outcomes in Portuguese children. *PLoS One*. 2013;8:e54370.
18. Ghossaini M, Meyre D, Lobbens S, et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. *BMC Med Genet*. 2005;6:11.
19. Milewicz A, Tworowska-Bardzińska U, Dunajska K, Jędrzejuk D, Lwow F. Relationship of PPARgamma2 polymorphism with obesity and metabolic syndrome in postmenopausal Polish women. *Exp Clin Endocrinol Diabetes*. 2009;117:628–632.
20. Passaro A, Dalla Nora E, Marcello C, et al. PPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome. *Cardiovasc Diabetol*. 2011;10:112.
21. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science*. 2007;316:1341–1345.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert

opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal>